John E. Friend II - 18 Mar 2026 Form 3 Insider Report for KAZIA THERAPEUTICS LTD (KZIA)

Role: Chief Executive Officer
Signature: /s/ Jeffrey Bonacorda, Attorney-in-Fact
Issuer symbol: KZIA
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 18:35:38 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Friend John E. II	Chief Executive Officer	THREE INTERNATIONAL TOWERS, LEVEL 24, 300 BARANGAROO AVE, SYDNEY, NSW, AUSTRALIA	/s/ Jeffrey Bonacorda, Attorney-in-Fact	18 Mar 2026	0001704021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	KZIA	American Depositary Share Option (Right to Buy)							18 Mar 2026	American Depositary Shares	30,000	$0.3770	Direct	F1, F2, F3
holding	KZIA	American Depositary Share Option (Right to Buy)							18 Mar 2026	American Depositary Shares	500,000	$6.58	Direct	F2, F3, F4
holding	KZIA	Ordinary Shares Option (Right to Buy)							18 Mar 2026	Ordinary Shares	3,000,000	$0.1323	Direct	F5, F6
holding	KZIA	Ordinary Shares Option (Right to Buy)							18 Mar 2026	Ordinary Shares	1,000,000	$0.1061	Direct	F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 22, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 22, 2024.
F2	Each ADS option is convertible into ADSs upon exercise.
F3	Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
F4	The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025.
F5	The Ordinary Shares subject to the option ("OS option") vest in three equal annual installments beginning on May 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on May 3, 2023.
F6	The exercise price is reported in U.S. dollars and reflects the conversion from AUD to USD at an exchange rate of 0.7075 USD per 1.00 AUD as of March 18, 2026.
F7	The Ordinary Shares subject to the OS option vest in two equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on March 3, 2023.

Remarks:

Exhibit 24 - Power of Attorney